Daraxonrasib Nearly Doubles Survival in Pancreatic Cancer Trial, Researchers Say
5 verified3 unconfirmed
A new drug, daraxonrasib, has shown a significant survival benefit for patients with advanced pancreatic cancer in a Phase 3 clinical trial. The drug targets the KRAS mutation, which has long been considered an “undruggable” target by scientists. Data from the trial was presented at the recent meeting of the American Society of Clinical Oncology. Researchers reported that the treatment nearly doubled overall survival for patients with metastatic pancreatic cancer who had received prior therapy. The drug, developed by Revolution Medicines, is taken orally once daily. Oncologists gave a standing ovation to the data presentation, reflecting the high level of interest in a potential new therapy for a disease with few effective options.
What’s verified
The drug daraxonrasib showed a survival benefit in a Phase 3 clinical trial for metastatic pancreatic cancer.
The trial involved patients who had received prior treatment for advanced disease.
Daraxonrasib targets the KRAS mutation, which drives more than 90% of pancreatic tumors.
Data from the trial was presented at the American Society of Clinical Oncology (ASCO) meeting in late May/early June 2026.
The drug is developed by Revolution Medicines.
Not yet confirmed
The specific survival numbers (6.7 months to 13.2 months and 60% risk reduction) come from a single source.
The most common side effects, including skin rash and stomatitis, are reported in only one source.
A patient named Leanna Stokes, who participated in the trial, is mentioned in one source as sharing her experience.
Key figures
Christopher Lieu, Professor of Medical Oncology, University of Colorado Anschutz (author of source material)
Revolution Medicines (company developing daraxonrasib)
Leanna Stokes (patient in the trial)
Sources: ScienceDaily, statnews.com
